Table 3.
Postoperative hypotension |
||||
---|---|---|---|---|
Variable |
All (n = 96) |
No, median (IQR) |
Yes, median (IQR) |
P |
Age (years), mean ± s.d. | 96 | 37.8 ± 14.5 | 37.5 ± 15.6 | 0.937 |
Chromogranin A | 96 | 196 (134–893) | 328 (163–776) | 0.520 |
24-h urine NMN f-ULN | 85 | 2.8 (1.1–3.6) | 5.0 (1.1–9.9) | 0.175 |
24-h urine MN f-ULN | 84 | 0.4 (0.3–1.4) | 0.4 (0.2–0.8) | 0.329 |
Plasma NMN f-ULN | 96 | 4.1 (1.8–8.7) | 7.3 (3.2–17.3) | 0.018 |
Plasma MN f-ULN | 96 | 0.5 (0.4–1.1) | 0.5 (0.4–0.7) | 0.797 |
Plasma dopamine f-ULN | 93 | 0.9 (0.4–1.8) | 1.1 (0.4–2.8) | 0.595 |
Tumor max dimension (cm) | 96 | 3.6 (2.5–5.8) | 3.9 (2.5–6.3) | 0.254 |
Number of tumors | 96 | 1 (1–2) | 2 (1–3) | 0.029 |
Total tumor volume (cm3) | 96 | 13.8 (4.6–45.3) | 15.78 (3.8–56.9) | 0.369 |
Duration of α-blockade (days) | 96 | 30.0 (17.3–65.5) | 38.0 (17.5–66.0) | 0.377 |
Number of BP medications, mean ± s.d. | 96 | 2.3 ± 0.9 | 2.6 ± 0.7 | 0.140 |
Preopeartive MAP | 96 | 89.7 (80.3-94.8) | 87.3 (82-95) | 0.724 |
Preoperative SBP | 96 | 124 (117-130) | 120 (115-128) | 0.361 |
Preoperative IVF hydration (mL), mean ± s.d. | 95 | 1280 ± 591 | 1250 ± 619 | 0.823 |
Estimated blood loss (mL) | 95 | 300 (100–800) | 300 (100–800) | 0.736 |
Surgery duration (min) | 96 | 247 (189–386) | 312 (242–365) | 0.446 |
IO crystalloid (mL) | 96 | 4300 (3000–6150) | 4500 (3500–6000) | 0.450 |
24-h postoperative IVF (mL) | 96 | 2872 (2385–3544) | 4058 (2871–5270) | 0.001 |
Increase in postoperative weight (kg), mean ± s.d. | 96 | 4.0 ± 3.7 | 6.4 ± 3.8 | 0.007 |
Return of bowel function (days) | 96 | 4.0 (3.0–5.0) | 4.0 (2.0–6.0) | 0.425 |
Length of stay (days) | 96 | 7.0 (6.0–9.0) | 7.0 (6.0–9.0) | 0.678 |
BP, antihypertensive; f-ULN, fold above upper limit of normal; IO, intraoperative; IQR, interquartile range; IVF, intravenous fluid; MAP, mean arterial pressure; max, maximum; MN, metanephrines; NMN, normetanephrine; SBP, systolic blood pressure. Bold indicates statistical significance, P<0.05.